SYNTOCINON
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNTOCINON is a synthetic oxytocin injection approved by Novartis in 1980 for obstetric and gynecological indications. The drug is administered via injection and represents a small-molecule therapeutic used primarily in labor induction and management of postpartum hemorrhage. Oxytocin is a naturally occurring hormone that stimulates uterine contractions and milk letdown.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely focused on lifecycle extension and defensive positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SYNTOCINON offers career exposure to mature product management, supply chain optimization, and healthcare market dynamics in obstetrics. Roles emphasize commercial efficiency, regulatory compliance, and defensive market strategy rather than innovation or launch execution.
ManagerVP
Worked on SYNTOCINON at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.